Sonoma Pharmaceuticals (SNOA) Earnings Analysis

Sonoma Pharmaceuticals (SNOA) next reports earnings on 2026-08-06, consensus EPS -0.3 USD. Last quarter (2026-06-16) it missed with EPS -0.33 USD vs -0.24 USD est (-37.5%). It has beaten estimates in 3/4 recent quarters (75%). Trailing P/E -0.61.

Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades

When does SNOA next report earnings?

Next earnings date2026-08-06
Consensus EPS estimate-0.3 USD
Revenue estimate0.00B

SNOA earnings history — beats and misses

Quarter (report date)EPS actualEPS est.SurpriseResult
2026-06-16-0.33 USD-0.24 USD-37.5%Miss
2025-08-07-0.37 USD-0.51 USD+27.5%Beat
2025-06-17-0.15 USD-0.73 USD+79.5%Beat
2025-02-05-0.59 USD-0.8 USD+26.3%Beat

Beat rate: 3/4 (75%) over reported quarters with consensus data.

SNOA valuation and analyst view

Trailing P/E-0.61
Trailing EPS-1.79955 USD
Price / book0.66
Dividend yield0.00%
Market cap0.00B
Analyst consensusBuy (1 buy / 1 hold / 0 sell)

Related research pages

Frequently asked questions

When is Sonoma Pharmaceuticals (SNOA)'s next earnings date?

Sonoma Pharmaceuticals is next scheduled to report on 2026-08-06, with a consensus EPS estimate of -0.3 USD and revenue estimate of 0.00B.

Did SNOA beat earnings last quarter?

In its 2026-06-16 report, SNOA posted EPS of -0.33 USD versus a -0.24 USD estimate — a miss of 37.5%.

What is SNOA's earnings track record?

Over the last 4 reported quarters with consensus data, SNOA beat estimates 3 times (75%).

What is SNOA's current P/E ratio and EPS?

SNOA trades at a trailing P/E of -0.61 on trailing EPS of -1.799548950848792 USD.

What do analysts rate SNOA?

Analyst consensus is "Buy" across 2 ratings (0 strong buy, 1 buy, 1 hold, 0 sell, 0 strong sell).